Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Indapamide slowly-releasing tablet

A technology for indapamide and sustained-release tablets, applied in the field of indapamide sustained-release tablets, which can solve the problems of unsuitable promotion, complicated granulation process, and high cost, and achieve low cost, rapid oral absorption, and easy acceptance Effect

Inactive Publication Date: 2003-02-05
严洁
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

U.S. Patent No. 5,334,392 discloses such a sustained-release tablet. The main component of the drug is indapamide, although this sustained-release tablet can reduce blood drug peaks, water electrolytes, metabolic disorders, and plasma concentrations compared with ordinary immediate-release tablets. Irregular changes and many other adverse reactions, but the auxiliary materials used include povidone, which is more expensive, which will increase the cost of the product and is not suitable for domestic promotion and use; in addition, the method needs to use water-containing alcohol , the granulation process is more complicated, so explosion-proof treatment is required in the preparation process, which is very unsafe
At present, there are no such drugs available in China

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0009] Based on 1000 indapamide sustained-release tablets, take 1.5 g of indapamide that was pulverized and screened through a 200-mesh sieve, and weigh 100 g of hydroxypropyl methylcellulose, 30 g of Crystalline cellulose, 10g sodium carboxymethyl starch and 60g sucrose, put these raw materials in a mixer and mix evenly, and make soft material with water, then use 30-mesh nylon mesh to make granules with less fine powder and neat without long strips . Dry the granules at a temperature of 60±2°C. After drying, sieve and size the granules to remove oversized particles, then add 10g of magnesium stearate screened through a 100-mesh sieve and mix evenly. Tablets were made into 1000 core tablets containing 1.5 mg of indapamide. At the same time, weigh 3g of methyl cellulose, add 70ml of distilled water under stirring conditions, and use ultrasonic treatment, then add 70ml of distilled water until the solution is clear, then add 15g of talcum powder and 8g of titanium dioxide and ...

Embodiment 2

[0011] Based on 1000 indapamide sustained-release tablets, 1.5g indapamide, 10g methylcellulose, 30g hydroxypropylcellulose, 5g lactose, 15g mannitol, 40g modified starch and 1g magnesium stearate Add-on and the same process of embodiment 1 are made into tablet cores. Simultaneously according to 20g hydroxyethyl cellulose, 8g talcum powder, 1g titanium dioxide, 5ml macrogol 400, 140ml distilled water and the ethanol add-on that adds to 500ml coating solution at last and make coating solution with the technique identical with embodiment 1 . The method of coating treatment is also the same as in Example 1.

Embodiment 3

[0013] Based on 1000 indapamide sustained-release tablets, according to the addition amount and embodiment of 1.5g indapamide, 60g methyl cellulose, 30g sodium alginate, 70g lactose, 30g modified starch and 8g magnesium stearate 1 The core is made by the same process. Simultaneously according to 8g hydroxypropyl cellulose, 2g talcum powder, 15g titanium dioxide, 5ml macrogol 400, 140ml distilled water and the ethanol add-on that is finally added to 500ml coating solution and the process identical with embodiment 1 makes coating solution . The method of coating treatment is also the same as in Example 1.

[0014] The indapamide sustained-release tablet provided by the present invention is a low-dose antihypertensive sustained-release drug containing 1.5 mg of indapamide active ingredient, and its appearance is a white film-coated tablet. Patients only need to take one tablet a day therapeutic concentrations can be achieved. Compared with low-dose indapamide sustained-release...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The indapamide slow-released tablet includes tablet core and coating, in which the tablet core is formed from indapamide, slow-releasing material, pore-forming agent, filling agent and lubricating agent in the ratio of 1.5g:40-150g:20-100g:10-100g:1-10g, and the coating is formed from film-forming amterial, antisticking agent, masking agent, polyethylene glycol 400, distrilled water and ethyl alcohol. The above-mentioned film-forming material, antisticking agent, masking agent, polyethylene glycol 400 and distilled water according to the ratio of 3-20g:2-15g:1-15g:5ml:140ml are added into the ethyl alcohol, and diluted with ethyl alcohol to 500ml to obtain the coating solution, then the outer layer of the tablet can be coated with said coating solution and dried so as to obtain the invented indapamide slow-release tablet.

Description

technical field [0001] The invention relates to a medicine, in particular to an indapamide sustained-release tablet which can treat hypertension and edema. Background technique [0002] Hypertension is a common and frequently-occurring disease with a high morbidity rate. If it is not treated properly or not treated in time, it may lead to serious complications and endanger the patient's physical and mental health, and even life-threatening. Indapamide is a first-line antihypertensive drug, which is clinically used to treat various hypertension and edema. It has the advantages of safety, effectiveness, convenience, rapid oral absorption, safety and reliable efficacy. Most of the indapamide currently used clinically is a common tablet of 2.5mg / tablet, and the adverse reactions caused by it increase due to the large daily dosage of the patients. In the future, the research on antihypertensive drugs will develop in the direction of long-acting drugs, that is, patients should be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/22A61K31/404A61P7/10A61P9/12
Inventor 严洁
Owner 严洁
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com